Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Endeavour Silver

    MCap

    CAD4,487m

    Last close

    CAD15.15

    ▲ 1.73 (12.89%)

    The Platform Group

    MCap

    EUR21m

    Last close

    EUR1.00

    ▲ 0.11 (12.61%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Newron Pharmaceuticals – executive interview

Newron Pharmaceuticals – executive interview

Newron Pharmaceuticals — 4 videos in collection

More on this equity

In this video, we speak with Stefan Weber, CEO of Newron Pharmaceuticals. We discuss the company’s registrational ENIGMA-TRS Phase III programme, the setting that evenamide is targeting and the licensing deals Newron has secured. Stefan also summarises the key milestones and catalysts that investors should watch out for across the next couple of years.

Newron Pharmaceuticals is a specialist in central nervous system drug development, and lead candidate evenamide is gearing up for two pivotal studies: ENIGMA-TRS 1 (international) and ENIGMA-TRS 2 (US focused). The candidate is backed by promising clinical data, specifically in the treatment-resistant schizophrenia sub-population. The Phase III programme is anticipated to conclude in Q426, after which, management plans to file for regulatory approval in all major geographies, including Europe and the US.

< Previous
Next >

You may also be interested in these:

Healthcare

Newron Pharmaceuticals – equity proposition

Healthcare

Webinar: The CNS renaissance Biotech companies at the forefront
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.